TEM 2X Long ETF

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Tempus AI(TEM.US) Tempus AI Publishes PRISM2 Cancer Pathology AI Study in Nature Medicine

👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

➤ 𝗧𝗲𝗺𝗽𝘂𝘀 AI published 𝗣𝗥𝗜𝗦𝗠𝟮 study results in Nature Medicine.

➤ 𝗣𝗥𝗜𝗦𝗠𝟮 was developed with researchers from 𝗠𝗶𝗰𝗿𝗼𝘀𝗼𝗳𝘁.

➤ Model matched or outperformed existing pathology foundation models.

➤ PRISM2 performs 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰, biomarker, and patient outcome prediction tasks.

➤ Fine-tuned PRISM2 achieved strong performance predicting 𝗰𝗼𝗹𝗼𝗿𝗲𝗰𝘁𝗮𝗹 𝗰𝗮𝗻𝗰𝗲𝗿 recurrence-free survival.

➤ Model enables diagnostic-grade precision for 𝗰𝗮𝗻𝗰𝗲𝗿 detection and prognosis.

➤ PRISM2 was trained on 𝟮.𝟯 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 whole-slide pathology images.

➤ Training included 𝟭𝟰 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 diagnostic question-answer pairs.

➤ Dataset was derived from nearly 𝟳𝟬𝟬,𝟬𝟬𝟬 pathology reports.

👉 𝗪𝗵𝘆 𝗧𝗵𝗶𝘀 𝗠𝗮𝘁𝘁𝗲𝗿𝘀:

➤ Advances AI-powered precision medicine and cancer diagnostics.

➤ Could improve biomarker detection and patient prognosis prediction.

➤ Demonstrates growing use of multimodal AI in clinical pathology research.

➤ Strengthens Tempus' position in AI-driven healthcare innovation.

👉 𝗘𝘅𝗽𝗲𝗿𝘁 𝗦𝘁𝗮𝘁𝗲𝗺𝗲𝗻𝘁:

𝗥𝗮𝘇𝗶𝗸 𝗬𝗼𝘂𝘀𝗳𝗶, Senior Vice President and General Manager of AI Products at Tempus:

“PRISM2 represents a true leap forward both in terms of scale and multi-modal AI capabilities. Our Pathology Foundation Models allow us to have a detailed understanding of tissue, unlocking clinical-grade precision and novel research applications capable of predicting patient outcomes and biomarker status. PRISM2 builds on this by aligning whole-slide pathology images with the language of clinical diagnosis through clinical dialogue training. It can seamlessly handle complex diagnostic and prognostic research tasks without requiring specialized fine-tuning, offering a powerful tool to advance precision oncology.”

$Tempus AI(TEM.US) | H.C. Wainwright 𝗺𝗮𝗶𝗻𝘁𝗮𝗶𝗻𝘀 𝗕𝘂𝘆 on 𝗧𝗲𝗺𝗽𝘂𝘀 𝗔𝗜 𝗜𝗻𝗰, cuts PT to $𝟱𝟲 from $𝟲𝟰

Analyst sees solid topline growth, but flags deceleration and a multi-year path to consistently positive operating cash flow.

$Tempus AI(TEM.US) Q2 EARNINGS

Adj. EPS: $(0.04) vs $(0.14) est

Sales: $382.486M vs $379.743M est

Raised FY2026 Sales Guidance

🟥 -0.63%

📢 𝗝𝗨𝗦𝗧 𝗜𝗡: $Tempus AI(TEM.US) Tempus AI Launches OneOme Pharmacogenomics Testing Nationwide

👉 𝗞𝗲𝘆 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:

➤ 𝗧𝗲𝗺𝗽𝘂𝘀 𝗔𝗜 launches 𝗢𝗻𝗲𝗢𝗺𝗲 pharmacogenomics testing nationwide.

➤ Launch follows the company's 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟱 acquisition of OneOme.

➤ 𝗥𝗶𝗴𝗵𝘁𝗠𝗲𝗱 𝗖𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 analyzes 𝟮𝟳 inherited genes.

➤ Standalone 𝗗𝗣𝗬𝗗 and 𝗨𝗚𝗧𝟭𝗔𝟭 pharmacogenomics tests are also available.

➤ Results are delivered in under 𝟱 days on average.

➤ FDA updated fluoropyrimidine safety labeling to recommend 𝗗𝗣𝗬𝗗 testing.

➤ Study estimates nearly 𝟯𝟬% of patients experience severe or fatal toxicities.

➤ Testing is integrated with Tempus's tissue and liquid biopsy platform.

➤ Platform enables clinicians to evaluate 𝗱𝗿𝘂𝗴-𝗴𝗲𝗻𝗲 interactions at the point of care.

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: Tempus AI to Acquire Personalis in $𝟏.𝟓 𝐁𝐢𝐥𝐥𝐢𝐨𝐧 Deal - $Tempus AI(TEM.US) $Personalis(PSNL.US)

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐓𝐞𝐦𝐩𝐮𝐬 𝐀𝐈 will acquire 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐬 in a $𝟏.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 transaction.

➤ Personalis shareholders will receive $𝟏𝟔.𝟐𝟓 per common share.

➤ Acquisition expands Tempus' 𝐦𝐢𝐧𝐢𝐦𝐚𝐥 𝐫𝐞𝐬𝐢𝐝𝐮𝐚𝐥 𝐝𝐢𝐬𝐞𝐚𝐬 (𝐌𝐑𝐃) capabilities.

➤ Deal combines Personalis' MRD technology with Tempus' 𝐀𝐈 and multimodal data platform.

➤ Tempus says MRD represents a $𝟐𝟎 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 market opportunity.

➤ Companies have partnered since 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟑.

➤ Personalis' NeXT Personal® test offers 𝐮𝐥𝐭𝐫𝐚𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐞 cancer recurrence monitoring.

➤ Medicare currently covers the test in 𝐭𝐡𝐫𝐞𝐞 indications.

➤ Acquisition aims to expand personalized cancer monitoring and biomarker discovery.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭𝐬:

𝐄𝐫𝐢𝐜 𝐋𝐞𝐟𝐤𝐨𝐟𝐬𝐤𝐲, CEO of Tempus:

“MRD is a large and rapidly growing market with the potential to truly transform how cancer patients are monitored, helping clinicians make faster and more informed decisions when cancer recurs. Through our existing collaboration with Personalis, we have already demonstrated the strength of combining highly sensitive MRD technology with our commercial infrastructure. With clinical adoption and reimbursement momentum building, we are collectively well positioned to capture this opportunity, which makes this acquisition particularly exciting."

𝐂𝐡𝐫𝐢𝐬 𝐇𝐚𝐥𝐥, CEO of Personalis:

“We believe this transaction represents an exciting next chapter for Personalis. Combining with Tempus gives us the scale, complementary capabilities and resources to accelerate innovation and deliver even greater value to patients, clinicians and biopharma partners. After conducting an exhaustive process, we are confident Tempus’ offer provides the most value to our shareholders and the fastest path to bringing Personalis’ industry-leading tests to patients suffering from cancer.”

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus Study Shows AI Improves Prostate Cancer Diagnosis and Lab Efficiency

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐀𝐫𝐭𝐢𝐜𝐮𝐥𝐚𝐭𝐞 𝐏𝐫𝐨 study results published in 𝐍𝐚𝐭𝐮𝐫𝐞 𝐃𝐢𝐠𝐢𝐭𝐚𝐥 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞.

➤ 𝐏𝐚𝐢𝐠𝐞 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐞 assisted pathologists in updating diagnoses for 𝐒% of patients.

➤ 𝐈.𝟑% of AI-assisted changes could potentially alter clinical management.

➤ Study evaluated biopsies from more than 𝐈,𝟎𝟎𝟎 patients across three UK NHS trusts.

➤ AI improved 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 consistency by detecting subtle cancer lesions.

➤ Laboratories reported results delivered nearly 𝐨𝐧𝐞 𝐝𝐚𝐲 sooner.

➤ AI reduced requests for additional 𝐢𝐦𝐦𝐮𝐧𝐨𝐡𝐢𝐬𝐭𝐨𝐜𝐡𝐞𝐦𝐢𝐬𝐭𝐫𝐲 (𝐈𝐇𝐂) staining.

➤ Findings indicate improved 𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐨𝐫𝐲 efficiency and resource utilization.

➤ Paige Prostate Suite is part of the 𝐓𝐞𝐦𝐩𝐮𝐬 intelligent diagnostics ecosystem.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

𝐑𝐚𝐳𝐢𝐤 𝐘𝐨𝐮𝐬𝐟𝐢, Senior Vice President and General Manager of AI Products at Tempus:

"The rigorous, real-world results in the Articulate Pro study are a massive step forward for the global adoption of digital pathology. Integration of the Paige Prostate Suite directly into routine workflows shows that AI doesn't just work in a sandbox; it can actively alleviate the immense pressure on overstretched laboratories, cut down reporting times and give pathologists an extra layer of confidence when making critical diagnostic decisions."

$Tempus AI(TEM.US) | Guggenheim reiterates 𝐁𝐮𝐲 on 𝐓𝐞𝐦𝐩𝐮𝐬 𝐀𝐈, 𝐫𝐚𝐢𝐬𝐞𝐬 𝐏𝐓 𝐭𝐨 $𝟔𝟓 𝐟𝐫𝐨𝐦 $𝟔𝟎

Analyst raises PT after meeting management, citing adjusted oncology volumes and improved ASP outlook from the recent investor day leading to higher estimates.

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI Partners With Angiosarcoma Awareness to Advance Rare Cancer Research

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ 𝐓𝐞𝐦𝐩𝐮𝐬 𝐀𝐈 partnered with 𝐀𝐧𝐠𝐢𝐨𝐬𝐚𝐫𝐜𝐨𝐦𝐚 𝐀𝐰𝐚𝐫𝐞𝐧𝐞𝐬𝐬 to accelerate rare cancer research.

➤ Collaboration will leverage Tempus' 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫, clinical, and AI analytics capabilities.

➤ Dataset includes approximately 𝟔𝟎𝟎 de-identified angiosarcoma patient records.

➤ Each record contains paired 𝐃𝐍𝐀 and 𝐑𝐍𝐀 sequencing data with clinical information where available.

➤ The dataset represents one of the 𝐥𝐚𝐫𝐠𝐞𝐬𝐭 known molecular resources for angiosarcoma.

➤ Angiosarcoma affects about 𝟏,𝟎𝟎𝟎 people annually in the United States.

➤ Research aims to identify 𝐝𝐢𝐬𝐞𝐚𝐬𝐞 𝐛𝐢𝐨𝐥𝐨𝐠𝐲 and potential therapeutic opportunities.

➤ Collaboration builds on the 𝐀𝐧𝐠𝐢𝐨𝐬𝐚𝐫𝐜𝐨𝐦𝐚 𝐏𝐫𝐨𝐣𝐞𝐜𝐭 launched in 2017.

👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:

➤ Larger datasets could improve 𝐩𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐦𝐞𝐝𝐢𝐜𝐢𝐧𝐞 for rare cancer patients.

➤ Collaboration may accelerate 𝐭𝐚𝐫𝐠𝐞𝐭 𝐝𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 and future treatment development.

➤ Demonstrates Tempus AI's expanding role in 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 oncology research.

👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

➤ "Angiosarcoma, like many rare cancers, has been understudied because the foundational knowledge needed to develop novel therapy has been limited. Precision medicine should not be limited by the availability of data, especially for patients with uncommon and aggressive cancers. By bringing together Tempus' multimodal molecular and clinical data with collaborative research efforts across the healthcare community, we can fulfill the promise of precision medicine by treating the right patient with the right therapy at the right time." — 𝐄𝐳𝐫𝐚 𝐂𝐨𝐡𝐞𝐧, MD, Chief Medical Officer of Oncology at Tempus.

➤ "Rare cancer research has long been constrained by scale. Patients are geographically dispersed, data is fragmented across institutions and no single organization sees enough cases to answer many of the most important biological and clinical questions. Tempus has assembled an extraordinary molecular and clinical oncology dataset, and the Angiosarcoma Project at the Broad Institute of MIT and Harvard has built one of the largest patient-partnered rare cancer resources in the world. Together, we have an opportunity to create an unprecedented view of angiosarcoma that could reveal new disease biology, identify therapeutic opportunities and establish a model for how collaborative data sharing can accelerate discovery across rare cancers." — 𝐂𝐨𝐫𝐫𝐢𝐞 𝐏𝐚𝐢𝐧𝐭𝐞𝐫, CEO of Angiosarcoma Awareness, Inc

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI Publishes Validation Study for FDA-Cleared ECG-AF Software

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Tempus AI publishes 𝐦𝐮𝐥𝐭𝐢-𝐬𝐢𝐭𝐞 validation of its 𝐄𝐂𝐆-𝐀𝐅 software.

➤ Software received 𝐅𝐃𝐀 𝐜𝐥𝐞𝐚𝐫𝐚𝐧𝐜𝐞 in 2024 for AF risk prediction.

➤ AI model predicts 𝐨𝐧𝐞-𝐲𝐞𝐚𝐫 risk of atrial fibrillation or flutter.

➤ Study results published in leading cardiology journal 𝐇𝐞𝐚𝐫𝐭 𝐑𝐡𝐲𝐭𝐡𝐦.

➤ Validation conducted across 𝐭𝐡𝐫𝐞𝐞 geographically distinct clinical sites.

➤ Study evaluated 𝐷4,017 patients aged 65 and older.

➤ ECG-AI risk score exceeded 𝐩𝐫𝐞-𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐞𝐝 performance thresholds.

➤ Data from study supported Tempus' 𝐅𝐃𝐀 𝐜𝐥𝐞𝐚𝐫𝐚𝐧𝐜𝐞 decision.

➤ Tool aims to enable 𝐞𝐚𝐫𝐥𝐲 𝐫𝐢𝐬𝐤 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 before AF diagnosis.

➤ Tempus says ECG-AF was its first 𝐅𝐃𝐀-𝐜𝐥𝐞𝐚𝐫𝐞𝐝 ECG-AI device.

Throwback Thursday... remember Tempus AI?

That's the stock Pelosi bought call options on in Jan 2025

Today $Tempus AI(TEM.US) is up 10% after FDA clearance

And is now up 47% since her trade was first published on 1/20/25

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI, Yale, and MSK Launch Open-Source Digital Pathology Consortium

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Tempus AI, 𝐘𝐚𝐥𝐞 𝐍𝐞𝐰 𝐇𝐚𝐯𝐞𝐧 and 𝐌𝐒𝐊 launch the IMS Consortium.

➤ Initiative aims to accelerate 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐩𝐚𝐭𝐡𝐨𝐥𝐨𝐠𝐲 standardization and adoption.

➤ Tempus will open source the 𝐏𝐚𝐢𝐠𝐞 𝐈𝐌𝐒 platform and key modules.

➤ Platform includes slide viewing, case management, and 𝐀𝐈 𝐨𝐫𝐜𝐡𝐞𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧 tools.

➤ Consortium seeks to build an open, interoperable digital pathology ecosystem.

➤ Focus includes AI-powered diagnostics, biomarker discovery, and workflow efficiency.

➤ Additional academic and industry members are expected to join over time.

💬 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:

“Pathology is entering a transformative new era,” said Razik Yousfi, SVP and GM of AI Products at Tempus.

“Advances in deep learning and AI foundation models are enabling digital pathology to generate powerful insights directly from whole slide images, from cancer detection to molecular profiling. As demand for diagnostic and biomarker testing continues to rise, digital pathology offers a unique opportunity to enhance patient care by optimizing tissue utilization, uncovering actionable biomarkers, and improving laboratory workflows. We are excited to collaborate with YNHH and MSK to help bring the full potential of digital pathology into clinical practice.”

“Digital pathology is transforming how we deliver diagnostics, advance translational research, and integrate AI into clinical care,” said Chen Liu, MD, PhD, Chief of Pathology at YNHH.

“We are excited to join the Tempus IMS Consortium as a founding member and collaborate with leading academic and industry partners to help build an open, scalable, and interoperable digital pathology ecosystem. Open innovation and shared standards will be essential to accelerating adoption, improving workflow efficiency, and enhancing patient care.”

"Digital pathology lacks opensource and openaccess clinical-grade solutions for on-prem/cloud slide viewing, case management, and AI deployment," said Saad Nadeem, PhD, Associate Attending Computer Scientist at MSK.

"This open source IMS initiative is an important first step, providing opportunities for companies/institutions to develop, deploy, validate, monitor, and disseminate AI solutions with standardized workflows. Building on MSK's longstanding commitment and leadership in digital pathology, we look forward to working with our IMS Consortium partners to democratize access to digital pathology worldwide."

⚡ 𝐔𝐏𝐃𝐀𝐓𝐄: $Tempus AI(TEM.US) Tempus AI Launches Next-Generation 𝐋𝐞𝐧𝐬 Agentic AI Platform

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Tempus AI unveils next-generation 𝐋𝐞𝐧𝐬 to accelerate drug development.

➤ Platform integrates multimodal data, 𝐀𝐈 𝐚𝐠𝐞𝐧𝐭𝐬, and scientific workflows.

➤ Built on over a decade of 𝐫𝐞𝐚𝐥-𝐰𝐨𝐫𝐥𝐝 𝐝𝐚𝐭𝐚 and oncology expertise.

➤ Supports analysis across 𝟖.𝟓𝐌+ de-identified patient records.

➤ Users can generate and execute complex 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐩𝐥𝐚𝐧𝐬 using natural language.

➤ Already utilized by 𝟏𝟗 of the top 𝟐𝟎 global biopharma companies.

➤ Platform aims to speed clinical trial design, biomarker validation, and evidence generation

⚡ 𝐔𝐏𝐃𝐀𝐓𝐄: $Tempus AI(TEM.US) Tempus AI Launches 𝐓𝐞𝐦𝐩𝐮𝐬 𝐏𝐫𝐞𝐯𝐢𝐞𝐰 for Faster Cancer Insights

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Tempus AI unveils 𝐓𝐞𝐦𝐩𝐮𝐬 𝐏𝐫𝐞𝐯𝐢𝐞𝐰 for rapid oncology decision support.

➤ Application delivers preliminary biomarker insights within ~𝟐𝟒 𝐡𝐨𝐮𝐫𝐬 of tissue receipt.

➤ AI helps bridge the gap before full 𝐠𝐞𝐧𝐨𝐦𝐢𝐜 𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐢𝐧𝐠 results arrive.

➤ Initial focus includes 𝐌𝐒𝐈-𝐇, 𝐄𝐆𝐅𝐑 mutations, and 𝐅𝐆𝐅𝐑 fusions.

➤ Early insights may accelerate 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐜𝐚𝐧𝐜𝐞𝐫 treatment planning.

➤ Predictions powered by 𝐏𝐚𝐢𝐠𝐞 𝐏𝐫𝐞𝐝𝐢𝐜𝐭 AI trained on millions of slides.

➤ Expands Tempus’ use of 𝐀𝐈-𝐝𝐫𝐢𝐯𝐞𝐧 precision medicine in clinical workflows

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) Tempus AI Reports Early Results From Multimodal Foundation Model

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ Tempus trained AI model on 𝟐.𝟓𝐌 longitudinal patient records.

➤ Dataset included 𝟐𝟓𝟎𝐌+ clinical note pages, images, and genomic sequences.

➤ Model achieved 𝐂-𝐢𝐧𝐝𝐞𝐱 𝐨𝐟 𝟎.𝟖𝟎𝟐 for overall survival prediction.

➤ High-risk versus low-risk patients showed 𝐡𝐚𝐳𝐚𝐫𝐝 𝐫𝐚𝐭𝐢𝐨 𝐨𝐟 𝟒.𝟓𝟒.

➤ AI demonstrated prognostic value across key clinical and molecular subgroups.

➤ Model successfully replicated outcomes from major lung cancer trials.

➤ Built on 𝟓𝟎𝟎+ 𝐩𝐞𝐭𝐚𝐛𝐲𝐭𝐞𝐬 of data spanning 𝟒𝟓𝐌+ patient journeys.

📢 𝐉𝐔𝐒𝐓 𝐈𝐍: $Tempus AI(TEM.US) FDA Approves Tempus AI’s xT CDx for Tumor-Only Genomic Profiling

👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:

➤ FDA grants 𝐭𝐮𝐦𝐨𝐫-𝐨𝐧𝐥𝐲 approval for Tempus AI’s 𝐱𝐓 𝐂𝐃𝐱 platform.

➤ Tempus becomes first lab with FDA-approved 𝐭𝐮𝐦𝐨𝐫-𝐨𝐧𝐥𝐲 and 𝐭𝐮𝐦𝐨𝐫-𝐧𝐨𝐫𝐦𝐚𝐥 CDx profiling.

➤ xT CDx is a 𝟔𝟒𝟖-𝐠𝐞𝐧𝐞 assay for comprehensive solid tumor profiling.

➤ Approval allows testing when matched blood or saliva samples are unavailable.

➤ Platform serves as a 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐨𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 for certain colorectal cancer therapies.

➤ Tempus plans to migrate its DNA tumor portfolio to 𝐅𝐃𝐀-𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 assays.

➤ Company expects an estimated $𝟐𝟎𝟎 𝐀𝐒𝐏 benefit beginning in 𝟐𝟎𝟐𝟕